Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CISH-inactivated autologous TILs + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CISH-inactivated autologous TILs | Autologous CISH-inactivated TILs|CISH inactivated TIL | CISH-inactivated autologous TILs are patient-derived tumor infiltrating lymphocytes engineered to have disruption of cytokine-induced SH2 protein (CISH), which potentially results increased anti-tumor immune response (PMID: 36007524). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|